• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

monicaas@unimelb.edu.au

Credentials


Position
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0002-8443-314X

Prof Monica Slavin

Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology

573 Scholarly works
28 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Subtherapeutic posaconazole exposure during delayed-release tablet prophylaxis in high-risk patients with haematological malignancies: rationale for routine therapeutic drug monitoring
    DOI: 10.1093/jac/dkag233
  • 2026

    Journal article

    Cytomegalovirus reactivation in patients with multiple myeloma receiving bispecific antibodies
    DOI: 10.1182/bloodadvances.2025019563
  • 2026

    Journal article

    Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort study.
    DOI: 10.1016/j.cmi.2026.06.019
  • 2024

    Research grants (ARC, NHMRC, MRFF)

    Transforming Infection Management in the Era of Emerging Cancer Therapies
  • 2022

    Journal article

    Cost-effectiveness of home-based care of febrile neutropenia in children with cancer
    DOI: 10.1002/pbc.29469
  • 2022

    Research grants (other domestic)

    Appropriate Antimicrobial Use: Scaling Surveillance Using Digital Health
  • 2022

    Research grants (ARC, NHMRC, MRFF)

    Improving Patient Outcomes Through Implementation of Digital and Diagnostic Innovations for Infections in Cancer
Monica Slavin

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Infections in the First 30 Days after Chimeric Antigen Receptor T-Cell Therapy in Patients Not Receiving Fluoroquinolone Prophylaxis.
    DOI: 10.1016/j.jtct.2026.03.040
  • 2026

    Journal article

    Longitudinal real-world surveillance of infection outcomes in CAR-T and bispecific therapy recipients: the CLARITY study protocol
    DOI: 10.1136/bmjopen-2025-111194
  • 2026

    Journal article

    Which trial do we need? Defining the optimal duration of antifungal therapy for invasive pulmonary aspergillosis
    DOI: 10.1016/j.cmi.2026.01.030
  • 2026

    Journal article

    Invasive mould infection in children – advances made or obstacles remaining?
    DOI: 10.1016/j.cmi.2025.11.023
  • 2026

    Journal article

    Invasive Fungal Disease in Allogeneic Hematopoietic Cell Transplantation: New Risk Factors and New Therapeutic Options in a Changing World
    DOI: 10.1111/tid.70197
  • 2026

    Journal article

    Diagnosis and risk factors for invasive mould disease—a round table discussion on directing antifungal therapy according to the available evidence
    DOI: 10.1093/jac/dkag062
  • 2026

    Journal article

    25 years of improvement in mortality in invasive aspergillosis in haematology patients: Will it be sustained or is it under threat?
    DOI: 10.1093/jac/dkag077

RECENT PROJECTS

  • 2025

    Research grants (ARC, NHMRC, MRFF)

    MITIGATE: Metagenomics and Integrated Transcriptomics for Infectious Disease Genomics and Translational Evaluation

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224